Role of DNA methylation in renal cell carcinoma

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Shenoy, Niraj ^a   Vallumsetla, Nishanth ^a   Zou, Yiyu ^a   Galeas, Jose Nahun ^a   Shrivastava, Makardhwaj ^a   Hu, Caroline ^a   Susztak, Katalin ^b   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DNA methylation; Epigenetics; Kidney cancer

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CONNEXIN 32; CYTOKERATIN 19; FRAGILE HISTIDINE TRIAD PROTEIN; MICRORNA; MICRORNA 9-1; MICRORNA 9-3; PLAKOGLOBIN; PROTEIN MSH2; PROTEIN P53; RAP1 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 5; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR GATA 5; UNCLASSIFIED DRUG; UVOMORULIN; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

APAF 1 GENE; BTG3 GENE; CANCER GROWTH; CARCINOGENESIS; CX32 GENE; DACH1 GENE; DAL1 GENE; DAPK 1 GENE; DKK1 GENE; DLK1 GENE; DNA METHYLATION; ECAD GENE; EPIGENETICS; FHIT GENE; GATA3 GENE; GATA5 GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GREM1 GENE; HIC1 GENE; HOXA5 GENE; HOXB13 GENE; HUMAN; JUP GENE; KIDNEY CARCINOMA; KILLIN GENE; KRT19 GENE; LRRC3B GENE; MSH2 GENE; NBK GENE; NONHUMAN; PCDH17 GENE; RAP1GAP GENE; REGULATORY SEQUENCE; REVIEW; SFRP1 GENE; SFRP2 GENE; SFRP5 GENE; SPINT2 GENE; TCF 21 GENE; TIMP3 GENE; TU3A GENE; UNC5C GENE; UQCRH GENE; VHL GENE; WIF 1 GENE; XAF 1 GENE; AGED; GENETICS; METABOLISM; MIDDLE AGED; PROCEDURES;

AGED; CARCINOMA, RENAL CELL; DNA METHYLATION; EPIGENOMICS; HUMANS; MIDDLE AGED;

EID: 84937417017     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0180-y     Document Type: Review

References (86)

1. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13(14):4042-5.
2. Morris MR et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29(14):2104-17.
3. Gumz ML et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(16):4740-9.
4. Gloerich M, Bos JL. Regulating Rap small G-proteins in time and space. Trends Cell Biol. 2011;21(10):615-23.
5. Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol. 2010;50:355-75.
6. Kim WJ, Gersey Z, Daaka Y. Rap1GAP regulates renal cell carcinoma invasion. Cancer Lett. 2012;320(1):65-71.
7. Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci USA. 2008;105(14):5396-401.
8. Bennett KL et al. Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer. 2011;50(8):654-61.
9. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837-51.
10. Kawakami K et al. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res. 2009;69(22):8603-10.
11. Hirata H et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer. 2011;128(8):1793-803.
12. Kawamoto K et al. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer. 2008;123(3):535-42.
13. Awakura Y et al. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep. 2008;20(5):1257-63.
14. Dahl E et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene. 2007;26(38):5680-91.
15. Kawakami K et al. Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer. 2011;128(3):541-50.
16. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167-79.
17. Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014;7(1):86.
18. Lujambio A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 2008;105(36):13556-61.
19. Hildebrandt MAT et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29(42):5724-8.
20. Brazil DP et al. BMP signalling: agony and antagony in the family. Trends Cell Biol. 2015;25(5):249-64.
21. van Vlodrop IJ et al. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol. 2010;176(2):575-84.
22. Ou YH et al. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J. 2007;26(17):3968-80.
23. Majid S et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009;30(4):662-70.
24. Leaman DW et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem. 2002;277(32):28504-11.
25. Reu FJ et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol. 2006;24(23):3771-9.
26. Ahmad ST et al. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumor Biol. 2012;33(2):395-402.
27. Christoph F et al. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 2006;95(12):1701-7.
28. Raveh T et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol. 2001;3(1):1-7.
29. Gillissen B et al. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J. 2003;22(14):3580-90.
30. Okuda H et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene. 2006;25(12):1733-42.
31. Tran YK et al. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999;59(1):35-43.
32. Yamada D et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer. 2006;118(4):916-23.
33. Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010;10(7):658-64.
34. Morris MR et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65(11):4598-606.
35. Syrigos KN et al. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol. 1998;160(5):1889-93.
36. Cerrato A et al. Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol. 1998;185(3):267-72.
37. Pantel K et al. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol. 1998;16(4):1407-13.
38. Smith LT et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA. 2006;103(4):982-7.
39. Ye YW et al. Down-regulation of TCF21 is associated with poor survival in clear cell renal cell carcinoma. Neoplasma. 2012;59(6):599-605.
40. Costa VL et al. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011;6(9):1120-30.
41. Chen WY et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123(3):437-48.
42. Wang CG et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006;8(9):1025-U109.
43. Jenal M et al. The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Cancer Res. 2009;7(6):916-22.
44. Eggers H et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. Int J Oncol. 2012;40(5):1650-8.
45. Kim M et al. LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer. Cancer Res. 2008;68(17):7147-55.
46. Haraldson K et al. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. Biochimie. 2012;94(5):1151-7.
47. Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors. Mol Cell Biol. 1993;13(7):3999-4010.
48. Peters I et al. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int. 2012;110(2 Pt 2):E144-52.
49. Morrissey C et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001;61(19):7277-81.
50. Peters I et al. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer. 2007;6:49.
51. Ellinger J et al. DNA hypermethylation in papillary renal cell carcinoma. BJU Int. 2011;107(4):664-9.
52. Kawai Y et al. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol. 2010;21(8):1612-7.
53. Costa VL et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2007;7:133.
54. Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer. 2004;4(12):978-87.
55. Cirulli V, Yebra M. Netrins: beyond the brain. Nat Rev Mol Cell Biol. 2007;8(4):296-306.
56. Lv D et al. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. Eur J Cancer. 2011;47(13):2068-76.
57. Bader BL, Jahn L, Franke WW. Low level expression of cytokeratins 8, 18 and 19 in vascular smooth muscle cells of human umbilical cord and in cultured cells derived therefrom, with an analysis of the chromosomal locus containing the cytokeratin 19 gene. Eur J Cell Biol. 1988;47(2):300-19.
58. Ju JH et al. Regulation of cell proliferation and migration by keratin19-induced nuclear import of early growth response-1 in breast cancer cells. Clin Cancer Res. 2013;19(16):4335-46.
59. Cao Y et al. Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch. 2000;436(2):119-26.
60. Labastie MC et al. The Gata-3 gene is expressed during human kidney embryogenesis. Kidney Int. 1995;47(6):1597-603.
61. Cooper SJ et al. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene. 2010;29(20):2905-15.
62. Tavares TS et al. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008;7(10):1607-18.
63. Qi JH et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9(4):407-15.
64. Masson D et al. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer. 2010;46(8):1430-7.
65. Bachman KE et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59(4):798-802.
66. Awakura Y et al. Methylation-associated silencing of TU3A in human cancers. Int J Oncol. 2008;33(4):893-9.
67. Kvasha S et al. Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett. 2008;265(2):250-7.
68. Kawakami T et al. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet. 2006;15(6):821-30.
69. Schmidt JV et al. The Dlk1 and Gtl2 genes are linked and reciprocally imprinted. Genes Dev. 2000;14(16):1997-2002.
70. Yano T et al. Tumor-suppressive effect of connexin 32 in renal cell carcinoma from maintenance hemodialysis patients. Kidney Int. 2003;63(1):381-1.
71. Yano T et al. Hypermethylation of the CpG island of connexin 32, a candiate tumor suppressor gene in renal cell carcinomas from hemodialysis patients. Cancer Lett. 2004;208(2):137-42.
72. Nojima D et al. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog. 2001;32(1):19-27.
73. Yoo KH et al. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol Int. 2010;60(10):661-6.
74. Clifford SC et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998;22(3):200-9.
75. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43-9.
76. Chu Q et al. DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. J Hematol Oncol. 2014;7(1):73.
77. Yoo KH, Park YK, Chang SG. DNA hypomethylation of interleukin 8 in clear cell renal cell carcinoma. Oncol Lett. 2013;5(1):39-42.
78. Dunker K et al. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens. 2008;72(2):137-48.
79. Cho M et al. Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol Carcinog. 2000;27(3):184-9.
80. Vanharanta S et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013;19(1):50-6.
81. Hagiwara H et al. 5-Aza-2′-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. Br J Pharmacol. 2008;153(7):1373-81.
82. Ricketts CJ et al. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics. 2013;5(1):16.
83. Hu CY et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res. 2014;20(16):4349-60.
84. Xu KY, Wu S. Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. Biomark Res. 2015;3:5.
85. Parikh K et al. Selective inhibitors of nuclear export (SINE) - a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78.
86. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.